2024 Kuwait Blood Typing, Grouping and Infectious Disease NAT Screening Market--2023 Supplier Shares and Strategies, 2023-2028 Volume and Sales Segment Forecasts for over 40 Individual Immunohematology and NAT Assays

May 2024 | | ID: 2765C83B0F49EN
Venture Planning Group

Abstracts

This unique report from LeadingMarketResearch.com provides information and analysis not available from any other published source.The report is available by section, and can be customized to specific information needs and budget.The database from LeadingMarketResearch.com provides the 2023 supplier shares and strategies, the 2023-2028 volume and sales forecasts for over 40 immunohematology and NAT assays, as well as comprehensive lists of companies developing or marketing new technologies and products by test, including:

Blood Typing and Grouping Tests

ABO, Antibody Panels, Antibody Screening/Indirect Antiglobulin, Antigen Typing (C, c, Duffy, E, e, I, i, Kell, Kidd, Le a, b, MN, P, S, s), Antiglobulin (Direct, C3 + IgG, IgG, C3), Crossmatching (Immediate Spin, Full Crossmatch), Rh (D, Du)

Infectious Disease Screening Tests

AIDS (HIV NAT, HIV-1/2), Cytomegalovirus, Hepatitis (HAV NAT, HBV NAT, HBs Ag, Anti-HBc, HCV NAT, HCV, ALT/SGPT), HTLV-I/II, Parvovirus B19 NAT, Syphilis, West Nile Virus NATThe companies analyzed in the report include:

• Abbott
• Beckman Coulter/Danaher
• Becton Dickinson
• Biokit
• bioMerieux
• Bio-Rad
• Diagast
• DiaSorin
• Fujirebio
• Grifols
• Hologic
• Immucor
• LabCorp
• Proteome Sciences
• Quest Diagnostics
• QuidelOrtho
• Roche
• Siemens Healthineers
• Tecan
• Thermo Fisher